接受阿替利珠单抗/贝伐单抗治疗的晚期肝细胞癌患者发生静脉曲张出血的风险 - Suppr

Suppr

超能文献

Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.

作者信息

Ha Yeonjung, Kim Jee Hyun, Cheon Jaekyung, Jeon Gyeong Sik, Kim Chan, Chon Hong Jae

机构信息

Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Gyeonggi-do, South Korea.

Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Gyeonggi-do, South Korea.

出版信息

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2421-2423.e2. doi: 10.1016/j.cgh.2022.07.035. Epub 2022 Aug 6.

DOI:10.1016/j.cgh.2022.07.035

PMID:35944830

Abstract

摘要

相似文献

Risk of Variceal Bleeding in Patients With Advanced Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab.接受阿替利珠单抗/贝伐单抗治疗的晚期肝细胞癌患者发生静脉曲张出血的风险

Clin Gastroenterol Hepatol. 2023 Aug;21(9):2421-2423.e2. doi: 10.1016/j.cgh.2022.07.035. Epub 2022 Aug 6.

Duodenal Variceal Rupture during Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma.贝伐珠单抗联合阿替利珠单抗治疗肝细胞癌致十二指肠静脉曲张破裂出血

Intern Med. 2023 May 15;62(10):1467-1472. doi: 10.2169/internalmedicine.0629-22. Epub 2022 Oct 5.

Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports.贝伐珠单抗联合替西木单抗治疗肝细胞癌患者发生静脉曲张出血后可考虑降低剂量或停药：病例报告。

Medicina (Kaunas). 2024 Jan 15;60(1):157. doi: 10.3390/medicina60010157.

Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.两例肝癌患者在接受阿替利珠单抗联合贝伐珠单抗治疗后食管静脉曲张迅速进展。

Clin J Gastroenterol. 2022 Apr;15(2):451-459. doi: 10.1007/s12328-022-01605-9. Epub 2022 Feb 18.

A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC.有静脉曲张出血史的 HCC 患者接受阿特珠单抗联合贝伐珠单抗治疗后会有进一步出血的风险。

Liver Int. 2022 Dec;42(12):2843-2854. doi: 10.1111/liv.15458. Epub 2022 Oct 26.

Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma-report a case and literature review.贝伐珠单抗联合阿替利珠单抗治疗肝细胞癌后门静脉高压进展：1 例报告并文献复习。

J Formos Med Assoc. 2024 Aug;123(8):916-919. doi: 10.1016/j.jfma.2024.03.019. Epub 2024 Apr 2.

Gastrointestinal bleeding in cirrhotic patients with hepatocellular carcinoma undergoing intrahepatic artery chemotherapy.

Gastrointest Endosc. 1997 Nov;46(5):430-4. doi: 10.1016/s0016-5107(97)70036-1.

Letter to the editor: A reminder to screen for varices! Atezolizumab/bevacizumab for HCC.致编辑的信：提醒筛查静脉曲张！阿替利珠单抗/贝伐单抗用于治疗肝细胞癌。

Hepatology. 2022 Oct;76(4):E78-E79. doi: 10.1002/hep.32556. Epub 2022 May 20.

Risk factors for esophageal variceal bleeding in patients with hepatocellular carcinoma.肝细胞癌患者食管静脉曲张出血的危险因素

Hepatogastroenterology. 2002 Jul-Aug;49(46):1039-44.

Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey.晚期肝细胞癌门静脉高压的筛查与管理：一项法国实践调查。

Clin Res Hepatol Gastroenterol. 2023 Feb;47(2):102059. doi: 10.1016/j.clinre.2022.102059. Epub 2022 Nov 28.

引用本文的文献

Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study.在中国晚期肝细胞癌中，乐伐替尼与贝伐单抗联合免疫检查点抑制剂及介入三联疗法的疗效比较：CLEAP 2302研究

Liver Cancer. 2025 Apr 3:1-19. doi: 10.1159/000545545.

Development and validation of a score model for predicting the risk of first esophagogastric variceal hemorrhage and mortality in patients with hepatocellular carcinoma.肝细胞癌患者首次食管胃静脉曲张出血风险及死亡率预测评分模型的开发与验证

Ann Med. 2025 Dec;57(1):2490210. doi: 10.1080/07853890.2025.2490210. Epub 2025 Apr 10.

ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.ALBI分级可对出血事件进行风险分层，并优化阿替利珠单抗和贝伐单抗治疗晚期肝癌后的预后预测。

J Hepatocell Carcinoma. 2025 Apr 4;12:671-683. doi: 10.2147/JHC.S462701. eCollection 2025.

Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis.接受阿替利珠单抗/贝伐单抗治疗的肝细胞癌患者的出血风险：一项系统评价和荟萃分析

Liver Cancer. 2024 May 22;13(6):590-600. doi: 10.1159/000539423. eCollection 2024 Dec.

Correspondence to letter to the editor on "Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis".致编辑的信，主题为“肝细胞癌伴门静脉血栓形成时经动脉放射性栓塞术与酪氨酸激酶抑制剂的比较”的通信

Clin Mol Hepatol. 2025 Jan;31(1):e93-e95. doi: 10.3350/cmh.2024.0943. Epub 2024 Nov 6.

Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma.两例不可切除肝细胞癌患者在接受阿替利珠单抗联合贝伐珠单抗治疗后出现静脉曲张出血。

Clin J Gastroenterol. 2024 Dec;17(6):1058-1066. doi: 10.1007/s12328-024-02031-9. Epub 2024 Aug 16.

Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report.阿替利珠单抗/贝伐珠单抗成功治疗后肝细胞癌患者发生致命性肿瘤内出血：一例报告

World J Clin Cases. 2024 Aug 6;12(22):5177-5183. doi: 10.12998/wjcc.v12.i22.5177.

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review.肝细胞癌中的免疫检查点抑制剂及其肝脏相关副作用：综述

Cancers (Basel). 2024 May 28;16(11):2042. doi: 10.3390/cancers16112042.

Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.系统治疗肝细胞癌相关门静脉高压症并发症的临床危险因素。

J Gastroenterol. 2024 Jun;59(6):515-525. doi: 10.1007/s00535-024-02097-9. Epub 2024 Apr 7.

Medicina (Kaunas). 2024 Jan 15;60(1):157. doi: 10.3390/medicina60010157.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验